October 6, 2021 07:18 AM EDT
R&D

Take­da flash­es red light on 'break­through' nar­colep­sy drug af­ter PhII tri­als turned up mys­te­ri­ous safe­ty sig­nal

Amber Tong

Take­da is bring­ing two Phase II nar­colep­sy tri­als to a pre­ma­ture end in the af­ter­math of a “safe­ty sig­nal.”

The tri­als test­ed TAK-994 as a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times